S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
BREAKING: Tiny biotech successfully treats blindness (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
BREAKING: Tiny biotech successfully treats blindness (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
BREAKING: Tiny biotech successfully treats blindness (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
BREAKING: Tiny biotech successfully treats blindness (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined

Viridian Therapeutics (VRDN) Competitors

$15.54
-0.20 (-1.27%)
(As of 09/22/2023 ET)
Compare
Today's Range
$15.35
$15.80
50-Day Range
$15.54
$22.93
52-Week Range
$15.35
$39.00
Volume
377,844 shs
Average Volume
591,950 shs
Market Capitalization
$678.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.57

VRDN vs. FLGT, CSTL, CDNA, PROG, CELC, NVTA, RDNT, FTRE, ARCT, and VREX

Should you be buying Viridian Therapeutics stock or one of its competitors? The main competitors of Viridian Therapeutics include Fulgent Genetics (FLGT), Castle Biosciences (CSTL), CareDx (CDNA), Progenity (PROG), Celcuity (CELC), Invitae (NVTA), RadNet (RDNT), Fortrea (FTRE), Arcturus Therapeutics (ARCT), and Varex Imaging (VREX). These companies are all part of the "medical" sector.

Viridian Therapeutics vs.

Fulgent Genetics (NASDAQ:FLGT) and Viridian Therapeutics (NASDAQ:VRDN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, community ranking, analyst recommendations and institutional ownership.

Fulgent Genetics received 212 more outperform votes than Viridian Therapeutics when rated by MarketBeat users. However, 65.31% of users gave Viridian Therapeutics an outperform vote while only 61.46% of users gave Fulgent Genetics an outperform vote.

CompanyUnderperformOutperform
Fulgent GeneticsOutperform Votes
244
61.46%
Underperform Votes
153
38.54%
Viridian TherapeuticsOutperform Votes
32
65.31%
Underperform Votes
17
34.69%

In the previous week, Fulgent Genetics had 2 more articles in the media than Viridian Therapeutics. MarketBeat recorded 2 mentions for Fulgent Genetics and 0 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.04 beat Fulgent Genetics' score of 0.00 indicating that Fulgent Genetics is being referred to more favorably in the media.

Company Overall Sentiment
Fulgent Genetics Positive
Viridian Therapeutics Neutral

Fulgent Genetics has higher revenue and earnings than Viridian Therapeutics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fulgent Genetics$307.38M2.66$143.40M-$1.64-16.66
Viridian Therapeutics$1.77M383.41-$129.87M-$4.87-3.19

Fulgent Genetics currently has a consensus target price of $42.33, indicating a potential upside of 54.95%. Viridian Therapeutics has a consensus target price of $42.57, indicating a potential upside of 173.95%. Given Fulgent Genetics' stronger consensus rating and higher possible upside, analysts clearly believe Viridian Therapeutics is more favorable than Fulgent Genetics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fulgent Genetics
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Viridian Therapeutics
0 Sell rating(s)
0 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
3.00

46.1% of Fulgent Genetics shares are owned by institutional investors. 31.8% of Fulgent Genetics shares are owned by company insiders. Comparatively, 1.4% of Viridian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Fulgent Genetics has a net margin of -15.84% compared to Fulgent Genetics' net margin of -13,462.86%. Viridian Therapeutics' return on equity of -3.29% beat Fulgent Genetics' return on equity.

Company Net Margins Return on Equity Return on Assets
Fulgent Genetics-15.84% -3.29% -3.03%
Viridian Therapeutics -13,462.86%-86.39%-49.05%

Fulgent Genetics has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Comparatively, Viridian Therapeutics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.

Summary

Fulgent Genetics beats Viridian Therapeutics on 12 of the 18 factors compared between the two stocks.


Get Viridian Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRDN vs. The Competition

MetricViridian TherapeuticsMedical laboratories IndustryMedical SectorNASDAQ Exchange
Market Cap$678.63M$1.16B$4.62B$6.26B
Dividend YieldN/A4.02%2.56%6.52%
P/E Ratio-3.196.81127.1112.64
Price / Sales383.4121.422,836.2563.14
Price / CashN/A6.0992.79100.49
Price / Book2.543.163.754.83
Net Income-$129.87M-$145.33M$121.91M$186.05M
7 Day Performance-11.35%-4.72%-2.61%-3.10%
1 Month Performance-17.34%-10.65%-2.06%-4.14%
1 Year Performance-24.89%-17.84%9.62%5.52%

Viridian Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FLGT
Fulgent Genetics
2.5724 of 5 stars
$28.52
-1.9%
$42.33
+48.4%
-28.2%$853.60M$618.97M-17.391,012News Coverage
Positive News
CSTL
Castle Biosciences
2.3459 of 5 stars
$16.77
+0.5%
$32.29
+92.5%
-33.0%$449.60M$137.04M-5.01582News Coverage
CDNA
CareDx
1.8059 of 5 stars
$8.02
+1.4%
$13.60
+69.6%
-52.5%$434.44M$321.79M-5.14727Positive News
PROG
Progenity
0 of 5 stars
$2.07
-1.0%
N/AN/A$381.29M$1.25M-0.74124Gap Up
CELC
Celcuity
1.972 of 5 stars
$10.05
+1.1%
$25.00
+148.8%
+12.4%$222.01MN/A-3.7945Analyst Report
News Coverage
NVTA
Invitae
2.1578 of 5 stars
$0.74
-3.9%
$2.08
+179.7%
-72.5%$205.76M$493.88M-0.231,700Analyst Downgrade
News Coverage
RDNT
RadNet
2.1271 of 5 stars
$28.10
+0.3%
$33.33
+18.6%
+60.5%$1.90B$1.43B-112.409,067
FTRE
Fortrea
0.9304 of 5 stars
$28.30
-1.5%
$29.00
+2.5%
N/A$2.51BN/A0.0019,000Gap Up
ARCT
Arcturus Therapeutics
2.3416 of 5 stars
$27.87
+2.7%
$38.78
+39.1%
+100.0%$741.34M$206M9.64170Analyst Report
News Coverage
Positive News
VREX
Varex Imaging
2.4549 of 5 stars
$18.62
-0.4%
$33.00
+77.2%
-12.0%$752.25M$859.40M26.232,300Positive News

Related Companies and Tools

This page (NASDAQ:VRDN) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -